About The Peptide Table
We grade 57 compounds on completed randomized human trials. We print no doses, and no seller pays for a place.
What do we do?
We grade compounds on completed randomized human trials, in one public Table. We answer the questions people ask before they buy. We publish a standard for judging what a seller shows you; the first seller scores are being checked and will be ranked on it. We write articles that start from a document, such as a drug label or a court record. Every record lists its sources, and each source carries the date it was checked.
What do we leave out?
We print no doses and no instructions for use. We give no personal medical advice, and we never pair a compound with a health promise. No seller is named on the site today; when the first scores are done, sellers will appear only in the ranking on the Standard page, each scored on the same public criteria, and none can pay for a place. There is no shop and no checkout anywhere on the site.
How are the facts checked?
Drafts are written with AI assistance. Each record lists its sources and the date it was last checked. Corrections are public, on the Corrections page. We never attribute a byline to an AI system.
How do we grade?
We count completed randomized human trials and grade each compound on that human evidence, from A to D. Approval is its own fact and sits beside the grade. The full rule is on the page How we count a trial.
| Grade | Label | What it means |
|---|---|---|
| Grade A | Large trials | Several completed randomized trials of a health outcome, at the scale that supports an approval |
| Grade B | Some trials | At least one completed randomized trial of a health outcome |
| Grade C | Small studies | Randomized studies that only measured the body's response |
| Grade D | No randomized trial | No completed randomized human trial. Case reports or uncontrolled studies at most |
Where do the facts come from?
We track trial records on ClinicalTrials.gov, approval and compounding status with the FDA, and marketing authorisations with the EMA. Where a record is silent, we say so. A source that is not a primary document is marked “Secondary” on the record.
Sources on the records: ClinicalTrials.gov, PubMed, the FDA and the EMA. Few records link a WADA document yet.
The Wednesday email
Every Wednesday: the week's new articles, cut to the lines that matter, in about two minutes.